MISSION
The AdMeTech Foundation is a 501(c)(3) nonprofit organization based in Boston, MA. Our mission is to end the prostate cancer crisis.

VISION
AdMeTech provides international leadership and conducts ground-breaking programs in research and education for facilitated development of accurate diagnostic tools for early detection and minimally-invasive treatment of prostate cancer to:

• Save lives, improve quality of life in millions of men, and reduce billions of dollars in health care costs, and

• End the era of blind prostate cancer care and create the future of image-guided, least invasive, and precisely targeted diagnosis and treatment that can be performed in outpatient clinics with minimal patient discomfort, complications, and costs.

APPROACH
To achieve these goals, AdMeTech has undertaken a public awareness campaign to recognize the prostate cancer crisis as a national priority and to increase public and private funding for research. As the result of this campaign, US Congress introduced historic legislation including the Prostate Research Imaging and Men’s Education (PRIME) Act and House Resolution 353. The PRIME Act, which calls for government funding of $650 million over 5 years for research and education to advance prostate cancer diagnostics is currently under consideration by the US Senate. House Resolution 353 was passed unanimously in June 2008 and expressed, “...the sense of the US House of Representatives that there should be increased support for research and development of advanced imaging technologies for prostate cancer detection and treatment.”

Massachusetts General Court and Boston City Council both issued resolutions recognizing the AdMeTech Foundation for its efforts in research and awareness to improve early detection and treatment of prostate cancer.

►Read Massachusetts General Court Resolution
►Read Boston City Council Resolution